Kiora Pharmaceuticals, Inc. Quarterly report pursuant to Section 13 or 15(d)

Quarterly report pursuant to Section 13 or 15(d)

Warrants

Warrants

6 Months Ended

Jun. 30, 2019

Warrants

Warrants

8. Warrants

The following is a summary of warrant activity for the six months ended June 30, 2019 and 2018:


		Weighted Average		Weighted Average
	Number of	Exercise		Remaining
	Warrants	Price		Term in Years
Outstanding at December 31, 2018	40,844,086	$	1.00	4.05
Exercised	(100,000)		0.32	3.80
Outstanding at June 30, 2019	40,744,086		1.00	3.55

Outstanding at December 31, 2017	9,455,961		3.26	4.23
Issued	35,156,250		0.32	4.80
Exercised	(2,356,875)		0.32	4.80
Outstanding at June 30, 2018	42,255,336	$	0.98	4.56

All of the warrant agreements provide for a cashless exercise in the event a registration statement covering the issuance of the shares of common stock underlying the warrants is not effective, whereby the number of warrants to be issued will be reduced by the number of shares which could be purchased from the proceeds of the exercise of the respective warrant. The outstanding warrants expire from 2020 through 2025.